485 related articles for article (PubMed ID: 25473153)
1. Risk of infections associated with biological treatment in inflammatory bowel disease.
Andersen NN; Jess T
World J Gastroenterol; 2014 Nov; 20(43):16014-9. PubMed ID: 25473153
[TBL] [Abstract][Full Text] [Related]
2. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
Magro F; Portela F
BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
[TBL] [Abstract][Full Text] [Related]
3. Significant risk and associated factors of active tuberculosis infection in Korean patients with inflammatory bowel disease using anti-TNF agents.
Kim ES; Song GA; Cho KB; Park KS; Kim KO; Jang BI; Kim EY; Jeon SW; Lee HS; Yang CH; Lee YK; Lee DW; Kim SK; Kim TO; Lee J; Kim HW; Jee SR; Park SJ; Kim HJ
World J Gastroenterol; 2015 Mar; 21(11):3308-16. PubMed ID: 25805938
[TBL] [Abstract][Full Text] [Related]
4. Biologic-Induced Infections in Inflammatory Bowel Disease: The TNF-α Antagonists.
McConachie SM; Wilhelm SM; Bhargava A; Kale-Pradhan PB
Ann Pharmacother; 2018 Jun; 52(6):571-579. PubMed ID: 29363355
[TBL] [Abstract][Full Text] [Related]
5. Corticosteroids and Thiopurines, But Not Tumor Necrosis Factor Antagonists, are Associated With Cytomegalovirus Reactivation in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.
Shukla T; Singh S; Tandon P; McCurdy JD
J Clin Gastroenterol; 2017; 51(5):394-401. PubMed ID: 27875356
[TBL] [Abstract][Full Text] [Related]
6. Infectious complications of TNF-α inhibitor monotherapy versus combination therapy with immunomodulators in inflammatory bowel disease: analysis of the Food and Drug Administration Adverse Event Reporting System.
Deepak P; Stobaugh DJ; Ehrenpreis ED
J Gastrointestin Liver Dis; 2013 Sep; 22(3):269-76. PubMed ID: 24078983
[TBL] [Abstract][Full Text] [Related]
7. Review article: chronic viral infection in the anti-tumour necrosis factor therapy era in inflammatory bowel disease.
Shale MJ; Seow CH; Coffin CS; Kaplan GG; Panaccione R; Ghosh S
Aliment Pharmacol Ther; 2010 Jan; 31(1):20-34. PubMed ID: 19681818
[TBL] [Abstract][Full Text] [Related]
8. Risk of tuberculosis in patients treated with anti-tumor necrosis factor therapy: a nationwide study in South Korea, a country with an intermediate tuberculosis burden.
Jung SM; Ju JH; Park MS; Kwok SK; Park KS; Kim HY; Yim HW; Park SH
Int J Rheum Dis; 2015 Mar; 18(3):323-30. PubMed ID: 25557144
[TBL] [Abstract][Full Text] [Related]
9. Risk of infections with biological agents.
Kopylov U; Afif W
Gastroenterol Clin North Am; 2014 Sep; 43(3):509-24. PubMed ID: 25110256
[TBL] [Abstract][Full Text] [Related]
10. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [I]: anti-tumor necrosis factor-α agents).
Baddley JW; Cantini F; Goletti D; Gómez-Reino JJ; Mylonakis E; San-Juan R; Fernández-Ruiz M; Torre-Cisneros J
Clin Microbiol Infect; 2018 Jun; 24 Suppl 2():S10-S20. PubMed ID: 29459143
[TBL] [Abstract][Full Text] [Related]
11. Nocardia infections among immunomodulated inflammatory bowel disease patients: A review.
Abreu C; Rocha-Pereira N; Sarmento A; Magro F
World J Gastroenterol; 2015 Jun; 21(21):6491-8. PubMed ID: 26074688
[TBL] [Abstract][Full Text] [Related]
12. [Non tuberculous anti-TNF associated opportunistic infections].
Marie I; Guglielmino E
Rev Med Interne; 2010 May; 31(5):353-60. PubMed ID: 20381217
[TBL] [Abstract][Full Text] [Related]
13. Hepatitis B Virus Screening and Reactivation in a National VA Cohort of Patients with Inflammatory Bowel Disease Treated with Tumor Necrosis Factor Antagonists.
Shah R; Ho EY; Kramer JR; Richardson P; Sansgiry S; El-Serag HB; Hou JK
Dig Dis Sci; 2018 Jun; 63(6):1551-1557. PubMed ID: 29663266
[TBL] [Abstract][Full Text] [Related]
14. The London position statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: safety.
Van Assche G; Lewis JD; Lichtenstein GR; Loftus EV; Ouyang Q; Panes J; Siegel CA; Sandborn WJ; Travis SP; Colombel JF
Am J Gastroenterol; 2011 Sep; 106(9):1594-602; quiz 1593, 1603. PubMed ID: 21844919
[TBL] [Abstract][Full Text] [Related]
15. Serious infections in patients with inflammatory bowel disease receiving anti-tumor-necrosis-factor-alpha therapy: an Australian and New Zealand experience.
Lawrance IC; Radford-Smith GL; Bampton PA; Andrews JM; Tan PK; Croft A; Gearry RB; Florin TH
J Gastroenterol Hepatol; 2010 Nov; 25(11):1732-8. PubMed ID: 21039834
[TBL] [Abstract][Full Text] [Related]
16. Opportunistic infections with anti-tumor necrosis factor-α therapy in inflammatory bowel disease: meta-analysis of randomized controlled trials.
Ford AC; Peyrin-Biroulet L
Am J Gastroenterol; 2013 Aug; 108(8):1268-76. PubMed ID: 23649185
[TBL] [Abstract][Full Text] [Related]
17. Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor.
Winthrop KL
Nat Clin Pract Rheumatol; 2006 Nov; 2(11):602-10. PubMed ID: 17075599
[TBL] [Abstract][Full Text] [Related]
18. Serum sickness, encephalitis and other complications of anti-cytokine therapy.
Vermeire S; Van Assche G; Rutgeerts P
Best Pract Res Clin Gastroenterol; 2009; 23(1):101-12. PubMed ID: 19258190
[TBL] [Abstract][Full Text] [Related]
19. A decade of infliximab: The Austrian evidence based consensus on the safe use of infliximab in inflammatory bowel disease.
Miehsler W; Novacek G; Wenzl H; Vogelsang H; Knoflach P; Kaser A; Dejaco C; Petritsch W; Kapitan M; Maier H; Graninger W; Tilg H; Reinisch W;
J Crohns Colitis; 2010 Sep; 4(3):221-56. PubMed ID: 21122513
[TBL] [Abstract][Full Text] [Related]
20. Risk of infections of biological therapies with accent on inflammatory bowel disease.
Nanau RM; Cohen LE; Neuman MG
J Pharm Pharm Sci; 2014; 17(4):485-531. PubMed ID: 25579431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
